October 25, 2017 09:47 AM EDT
R&D
Pharma

The Med­i­cines Com­pa­ny brings out the ax, look­ing to jet­ti­son hun­dreds of jobs in top-to-bot­tom re­struc­tur­ing

John Carroll

Editor & Founder

The Med­i­cines Com­pa­ny CEO Clive Mean­well is cir­cling all the wag­ons around its late-stage PC­SK9 de­vel­op­ment plans for in­clisir­an.

The Al­ny­lam part­ner said to­day that …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times